See more : XBiotech Inc. (XBIT) Income Statement Analysis – Financial Results
Complete financial analysis of AstraZeneca PLC (AZN.ST) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of AstraZeneca PLC, a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
- Sata Construction Co., Ltd. (1826.T) Income Statement Analysis – Financial Results
- Immobiliare Grande Distribuzione SIIQ S.p.A. (IGD.MI) Income Statement Analysis – Financial Results
- Investment Friends SE (IFR.WA) Income Statement Analysis – Financial Results
- Sihuan Pharmaceutical Holdings Group Ltd. (SHPHF) Income Statement Analysis – Financial Results
- United American Petroleum Corp. (UAPC) Income Statement Analysis – Financial Results
AstraZeneca PLC (AZN.ST)
About AstraZeneca PLC
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 45.81B | 44.35B | 37.42B | 26.62B | 24.38B | 22.09B | 22.47B | 23.00B | 24.71B | 26.10B | 25.71B | 27.97B | 33.59B | 33.27B | 32.80B | 31.60B | 29.56B | 26.48B | 23.95B | 21.43B | 18.85B | 17.85B | 23.57B | 18.12B | 18.44B | 9.15B | 8.59B | 9.18B | 7.57B | 7.00B | 6.57B | 6.03B | 7.35B | 7.35B |
| Cost of Revenue | 8.04B | 12.39B | 12.44B | 5.30B | 4.92B | 4.94B | 4.32B | 4.13B | 4.65B | 5.84B | 5.26B | 5.39B | 6.03B | 6.39B | 5.78B | 6.60B | 6.00B | 5.56B | 5.36B | 5.19B | 4.47B | 4.52B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 37.77B | 31.96B | 24.98B | 21.32B | 19.46B | 17.15B | 18.15B | 18.88B | 20.06B | 20.25B | 20.45B | 22.58B | 27.57B | 26.88B | 27.03B | 25.00B | 23.56B | 20.92B | 18.59B | 16.23B | 14.38B | 13.33B | 23.57B | 18.12B | 18.44B | 9.15B | 8.59B | 9.18B | 7.57B | 7.00B | 6.57B | 6.03B | 7.35B | 7.35B |
| Gross Profit Ratio | 82.45% | 72.06% | 66.76% | 80.09% | 79.82% | 77.66% | 80.78% | 82.06% | 81.20% | 77.61% | 79.54% | 80.72% | 82.06% | 80.80% | 82.40% | 79.12% | 79.69% | 79.00% | 77.64% | 75.76% | 76.29% | 74.67% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 10.94B | 9.76B | 9.74B | 5.99B | 5.96B | 5.93B | 5.76B | 5.89B | 6.00B | 5.58B | 4.82B | 5.24B | 5.52B | 5.32B | 4.41B | 4.95B | 5.09B | 3.90B | 3.38B | 3.47B | 3.45B | 3.07B | 3.97B | 2.89B | 2.92B | 1.18B | 1.08B | 1.03B | 848.32M | 809.84M | 767.71M | 676.44M | 703.57M | 704.06M |
| General & Administrative | -197.00M | 0.00 | 0.00 | 0.00 | 11.68B | 0.00 | 10.23B | 9.41B | 11.11B | 13.00B | 12.21B | 9.84B | 11.16B | 10.45B | 11.33B | 11.20B | 10.61B | 9.32B | 8.91B | 8.27B | 6.86B | 6.00B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 18.22B | 18.96B | 15.68B | 11.69B | 11.85B | 10.36B | 10.54B | 9.74B | 11.45B | 13.32B | 12.51B | 10.16B | 11.51B | 335.00M | 298.00M | 10.64B | 10.13B | 9.32B | 8.91B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 18.03B | 18.96B | 15.68B | 11.69B | 11.85B | 10.36B | 10.54B | 9.74B | 11.45B | 13.32B | 12.51B | 10.16B | 11.51B | 10.78B | 11.63B | 10.64B | 10.13B | 9.32B | 8.91B | 8.27B | 6.86B | 6.00B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | 618.00M | -514.00M | -1.49B | -1.53B | -1.54B | -650.00M | -10.44B | -9.74B | -11.63B | -13.76B | -12.77B | -970.00M | 0.00 | 0.00 | -553.00M | -11.16B | -10.86B | -9.85B | -9.10B | -78.00M | -91.00M | -31.02M | 13.61B | 10.75B | 10.70B | 6.00B | 5.69B | 6.28B | 5.04B | 5.00B | 4.78B | 4.41B | 5.38B | 5.34B |
| Operating Expenses | 29.58B | 28.20B | 23.92B | 16.16B | 16.27B | 13.77B | 14.47B | 13.97B | 15.95B | 18.12B | 16.74B | 14.43B | 16.25B | 15.39B | 15.49B | 15.45B | 14.50B | 12.70B | 12.09B | 11.69B | 10.27B | 8.97B | 17.58B | 13.64B | 13.62B | 7.17B | 6.77B | 7.32B | 5.89B | 5.81B | 5.55B | 5.09B | 6.08B | 6.04B |
| Cost & Expenses | 37.62B | 40.59B | 36.36B | 21.46B | 21.19B | 18.70B | 18.79B | 18.10B | 20.59B | 23.96B | 22.00B | 19.83B | 22.28B | 21.78B | 21.26B | 22.05B | 20.50B | 18.26B | 17.45B | 16.88B | 14.74B | 13.49B | 17.58B | 13.64B | 13.62B | 7.17B | 6.77B | 7.32B | 5.89B | 5.81B | 5.55B | 5.09B | 6.08B | 6.04B |
| Interest Income | 301.00M | 95.00M | 43.00M | 87.00M | 172.00M | 138.00M | 113.00M | 67.00M | 46.00M | 78.00M | 50.00M | 528.00M | 552.00M | 516.00M | 462.00M | 854.00M | 959.00M | 888.00M | 665.00M | 532.00M | 91.00M | 31.02M | 284.13M | 268.85M | 164.92M | 36.52M | 76.04M | 71.93M | 40.18M | 28.14M | 50.29M | 42.47M | 54.26M | 40.51M |
| Interest Expense | 1.59B | 1.35B | 1.30B | 1.31B | 1.43B | 1.42B | 1.51B | 1.38B | 1.08B | 963.00M | 495.00M | 958.00M | 980.00M | 1.03B | 1.20B | 1.32B | 1.07B | 561.00M | 500.00M | 454.00M | 0.00 | 0.00 | 134.81M | 131.44M | 166.92M | 106.23M | 100.84M | 109.60M | 95.80M | 117.26M | 202.65M | 283.62M | 392.95M | 389.65M |
| Depreciation & Amortization | 4.93B | 5.25B | 4.10B | 2.90B | 3.76B | 3.75B | 3.04B | 2.36B | 2.85B | 3.28B | 4.58B | 2.52B | 2.55B | 2.74B | 2.09B | 2.62B | 1.86B | 1.35B | 1.33B | 1.27B | 1.29B | 960.47M | 1.17B | 929.02M | 997.51M | 408.33M | 357.07M | 371.61M | 299.77M | 276.72M | 254.42M | 242.67M | 291.91M | 300.91M |
| EBITDA | 13.42B | 9.09B | 5.11B | 8.08B | 6.71B | 7.11B | 6.62B | 7.28B | 6.96B | 5.49B | 8.34B | 10.68B | 15.39B | 14.74B | 13.95B | 12.62B | 9.95B | 9.56B | 7.83B | 5.82B | 5.30B | 4.97B | 5.02B | 4.91B | 4.50B | 3.25B | 2.24B | 2.15B | 1.35B | 1.48B | 1.37B | 687.06M | 1.68B | 1.37B |
| EBITDA Ratio | 29.30% | 21.03% | 20.22% | 31.45% | 28.77% | 32.44% | 30.14% | 31.71% | 28.31% | 21.04% | 32.46% | 40.02% | 42.91% | 44.34% | 42.96% | 41.22% | 40.17% | 39.47% | 35.47% | 29.62% | 29.14% | 29.97% | 31.76% | 31.57% | 28.54% | 26.24% | 26.40% | 24.31% | 23.15% | 23.42% | 20.88% | 19.93% | 22.73% | 20.71% |
| Operating Income | 8.19B | 3.76B | 1.06B | 5.16B | 2.92B | 3.39B | 3.68B | 4.90B | 4.11B | 2.14B | 3.71B | 8.15B | 12.80B | 11.49B | 11.54B | 9.14B | 8.09B | 8.22B | 6.50B | 4.55B | 4.11B | 4.36B | 5.66B | 3.67B | 2.67B | 1.82B | 1.79B | 1.79B | 1.28B | 1.03B | 1.04B | 429.22M | 1.28B | 1.16B |
| Operating Income Ratio | 17.88% | 8.47% | 2.82% | 19.39% | 11.99% | 15.33% | 16.37% | 21.31% | 16.65% | 8.19% | 14.44% | 29.13% | 38.09% | 34.55% | 35.19% | 28.94% | 27.38% | 31.03% | 27.15% | 21.22% | 21.81% | 24.42% | 23.99% | 20.23% | 14.50% | 19.91% | 20.85% | 19.45% | 16.93% | 14.71% | 15.86% | 7.11% | 17.36% | 15.75% |
| Total Other Income/Expenses | -1.29B | -1.26B | -1.32B | -1.25B | -1.38B | -1.39B | -1.45B | -1.35B | -1.05B | -891.00M | -445.00M | -502.00M | -512.00M | -517.00M | -736.00M | -463.00M | -111.00M | 327.00M | 165.00M | 297.00M | 70.00M | 4.85M | 102.00M | 185.21M | 126.00M | 697.00M | -3.31M | -116.45M | -324.49M | 0.00 | -105.02M | -274.52M | -282.55M | -474.52M |
| Income Before Tax | 6.90B | 2.50B | -265.00M | 3.92B | 1.55B | 1.99B | 2.23B | 3.55B | 3.07B | 1.25B | 3.27B | 7.72B | 12.37B | 10.98B | 10.81B | 8.68B | 7.98B | 8.54B | 6.67B | 4.84B | 4.20B | 4.04B | 5.83B | 3.85B | 1.96B | 1.73B | 1.79B | 1.67B | 956.49M | 1.03B | 936.34M | 154.70M | 993.60M | 682.84M |
| Income Before Tax Ratio | 15.06% | 5.64% | -0.71% | 14.71% | 6.35% | 9.02% | 9.91% | 15.44% | 12.42% | 4.77% | 12.71% | 27.59% | 36.82% | 32.99% | 32.94% | 27.47% | 27.01% | 32.27% | 27.84% | 22.61% | 22.29% | 22.63% | 24.74% | 21.25% | 10.62% | 18.97% | 20.81% | 18.18% | 12.64% | 14.71% | 14.26% | 2.56% | 13.51% | 9.29% |
| Income Tax Expense | 938.00M | -792.00M | -380.00M | 772.00M | 321.00M | -57.00M | -641.00M | 146.00M | 243.00M | 11.00M | 696.00M | 1.39B | 2.35B | 2.90B | 3.26B | 2.55B | 2.36B | 2.48B | 1.94B | 1.16B | 1.14B | 1.18B | 1.66B | 1.30B | 814.60M | 547.76M | 570.32M | 548.00M | 414.12M | 328.31M | 279.57M | 15.17M | 312.49M | 231.47M |
| Net Income | 5.96B | 3.29B | 112.00M | 3.20B | 1.34B | 2.16B | 3.00B | 3.50B | 2.83B | 1.23B | 2.56B | 6.30B | 9.98B | 8.05B | 7.52B | 6.10B | 5.60B | 6.04B | 4.71B | 3.66B | 3.04B | 2.84B | 4.16B | 2.54B | 1.14B | 1.19B | 1.21B | 1.10B | 519.19M | 692.59M | 637.54M | 121.34M | 645.56M | 428.22M |
| Net Income Ratio | 13.00% | 7.41% | 0.30% | 12.01% | 5.47% | 9.76% | 13.36% | 15.21% | 11.43% | 4.73% | 9.94% | 22.51% | 29.72% | 24.21% | 22.93% | 19.31% | 18.93% | 22.83% | 19.65% | 17.10% | 16.11% | 15.90% | 17.63% | 14.02% | 6.20% | 12.96% | 14.05% | 11.99% | 6.86% | 9.89% | 9.71% | 2.01% | 8.78% | 5.83% |
| EPS | 3.81 | 2.12 | 0.08 | 2.44 | 1.03 | 1.70 | 2.37 | 2.77 | 2.23 | 0.98 | 2.04 | 4.95 | 7.29 | 5.60 | 5.19 | 4.20 | 3.74 | 3.86 | 2.91 | 2.18 | 1.77 | 1.64 | 1.65 | 1.43 | 0.64 | 1.47 | 1.27 | 1.16 | 0.55 | 0.73 | 0.75 | 0.17 | 0.90 | 0.60 |
| EPS Diluted | 3.81 | 2.11 | 0.08 | 2.44 | 1.03 | 1.70 | 2.37 | 2.76 | 2.23 | 0.98 | 2.04 | 4.94 | 7.25 | 5.57 | 5.19 | 4.20 | 3.73 | 3.85 | 2.91 | 2.18 | 1.77 | 1.64 | 1.65 | 1.43 | 0.64 | 1.46 | 1.27 | 1.16 | 0.55 | 0.73 | 0.75 | 0.17 | 0.90 | 0.60 |
| Weighted Avg Shares Out | 1.56B | 1.55B | 1.42B | 1.31B | 1.30B | 1.27B | 1.27B | 1.27B | 1.26B | 1.26B | 1.25B | 1.26B | 1.36B | 1.44B | 1.45B | 1.45B | 1.50B | 1.56B | 1.62B | 1.67B | 1.71B | 1.73B | 1.76B | 1.77B | 1.78B | 1.78B | 948.00M | 947.00M | 946.00M | 946.00M | 850.00M | 716.59M | 716.59M | 716.59M |
| Weighted Avg Shares Out (Dil) | 1.56B | 1.56B | 1.43B | 1.31B | 1.30B | 1.27B | 1.27B | 1.27B | 1.27B | 1.26B | 1.25B | 1.26B | 1.37B | 1.45B | 1.45B | 1.45B | 1.50B | 1.57B | 1.62B | 1.68B | 1.71B | 1.73B | 1.76B | 1.77B | 1.78B | 1.78B | 951.00M | 947.00M | 946.00M | 946.00M | 850.00M | 716.59M | 716.59M | 716.59M |
Source: https://incomestatements.info
Category: Stock Reports